title: Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
abstract: Novel anticancer compounds are being developed that attempt to exploit the unique properties of the vascular endothelium, which supplies rapidly dividing neoplasms. The goal of these vascular targeting agents (VTAs) or endothelial disrupting agents is to cause rapid shutdown of tumor blood supply with subsequent tumor death from hypoxia and nutrient deprivation. VTAs are classified into two broad categories: biologic therapies or small molecule compounds. A variety of VTAs are in early clinical development. These agents have demonstrated clinical activity in phase I trials and are being evaluated with cytotoxic chemotherapy and radiotherapy.
authors.affiliation: Developmental Therapeutics Program, Case Comprehensive Cancer Center, University Hospitals of Cleveland and Cleveland Clinic Foundation, 11100 Euclid Avenue, BHC-6, Cleveland, OH 44106, USA. matthew.cooney@uhhs.com
authors.forename: Matthew M
authors.initials: MM
authors.lastname: Cooney
authors.forename: Jose
authors.initials: J
authors.lastname: Ortiz
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Bukowski
authors.forename: Scot C
authors.initials: SC
authors.lastname: Remick
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D004730:Endothelium, Vascular / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D009943:Organophosphorus Compounds / Q000494:pharmacology; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use; D044004:Xanthones / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; C455219:N-acetylcochinol-O-phosphate; D009943:Organophosphorus Compounds; D013267:Stilbenes; D044004:Xanthones; C066668:vadimezan; C058728:fosbretabulin
references.citation: Cancer Res. 1998 Apr 1;58(7):1408-16
references.pmid: 9537241
references.citation: Anticancer Drug Des. 1999 Dec;14(6):539-48
references.pmid: 10834274
references.citation: Cancer Res. 1989 Dec 1;49(23):6449-65
references.pmid: 2684393
references.citation: Invest New Drugs. 2002 Aug;20(3):281-95
references.pmid: 12201491
references.citation: Cancer Res. 1999 Apr 1;59(7):1626-34
references.pmid: 10197639
references.citation: Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):96-100
references.pmid: 14734457
references.citation: Cancer Metastasis Rev. 1990 Sep;9(2):137-47
references.pmid: 2253313
references.citation: Proc Natl Acad Sci U S A. 1988 Dec;85(24):9533-7
references.pmid: 3200838
references.citation: Semin Radiat Oncol. 1996 Jan;6(1):46-58
references.pmid: 10717161
references.citation: Cancer Res. 1999 Jul 1;59(13):3192-8
references.pmid: 10397265
references.citation: Nature. 1996 Jan 4;379(6560):88-91
references.pmid: 8538748
references.citation: Neuroreport. 1996 Nov 4;7(15-17):2575-9
references.pmid: 8981426
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2823-30
references.pmid: 12807935
references.citation: Scanning Microsc. 1995;9(4):1233-43; discussion 1243-4
references.pmid: 8819901
references.citation: Br J Cancer. 1968 Jun;22(2):258-73
references.pmid: 5660132
references.citation: Clin Cancer Res. 2004 Jan 15;10 (2):415-27
references.pmid: 14760060
references.citation: Cancer Res. 1993 Sep 15;53(18):4161-3
references.pmid: 7689928
references.citation: Cancer Res. 1997 May 15;57(10):1829-34
references.pmid: 9157969
references.citation: Br J Cancer. 2003 Jun 16;88(12 ):1844-50
references.pmid: 12799625
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2815-22
references.pmid: 12807934
references.citation: Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7866-71
references.pmid: 12060733
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3826-40
references.pmid: 12228202
references.citation: J Clin Oncol. 2003 Dec 1;21(23):4428-38
references.pmid: 14645433
references.citation: Cancer Res. 2002 Jun 15;62(12):3408-16
references.pmid: 12067983